NervGen Pharma Corp. NGEN
Updated: 9 Aug 2026
No signal published yet
We already track NervGen Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow NervGen Pharma Corp.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NervGen Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, NervGen Pharma reported positive results from independent biomechanical gait analyses in its Phase 1b/2a CONNECT SCI study, showing genuine neural recovery with lead candidate NVG-291. During the same month, the company announced the pricing of a 60 million USD public offering of securities to support late-stage clinical development. This followed alignment with the U.S. FDA in April 2026 on the study design for its Phase 3 registrational study, RESTORE, in chronic tetraplegia.
What Firelda Watch includes for NervGen Pharma Corp.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow NervGen Pharma Corp.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NervGen Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more